I. PURPOSE

This Policy applies to ACC, ALTCS E/PD, DCS/CHP (CHP), DES/DDD (DDD), and RBHA Contractors. This Policy establishes requirements for cost settlement for Coronavirus Disease of 2019 (COVID-19) vaccine costs and Vaccine Administration Costs for October 1, 2021, to September 30, 2022 (Contract Year Ending [CYE] 22). The Contractor is not contractually at risk for the cost of the vaccine or the Vaccine Administration Costs during CYE 22. The anticipated costs have not been included in the CYE 22 capitation rates; therefore, the Contractor will be provided payment via cost settlement as delineated in this Policy.

II. DEFINITIONS

For purposes of this Policy:

**PREMIUM TAX**

The tax imposed pursuant to A.R.S. § 36-2905 and A.R.S. § 36-2944.01 for all payments made to the Contractor for the Contract year.

**VACCINE ADMINISTRATION COST**

The cost of administering the vaccine. This is the cost of administering the COVID-19 vaccine using the CMS 1500 medical form, in the 837P format or through the point-of-sale (POS) system. The COVID-19 vaccines are provided at no charge from the Federal government at the time of publication.

III. POLICY

A. GENERAL

This cost settlement shall relate solely to COVID-19 vaccine cost, if not provided by the Federal government at no charge, and Vaccine Administration Costs made by the Contractor for Title XIX and Title XXI members using the following list of approved Current Procedural Terminology (CPT) codes:
0001A Pfizer-BioNTech COVID-19 Vaccine Administration First Dose
0002A Pfizer-BioNTech COVID-19 Vaccine Administration Second Dose
0003A Pfizer-BioNTech COVID-19 Vaccine Administration Third Dose
0004A Pfizer-BioNTech COVID-19 Vaccine Administration Booster
91300 Pfizer-BioNTech COVID-19 Vaccine
0011A Moderna COVID-19 Vaccine Administration First Dose
0012A Moderna COVID-19 Vaccine Administration Second Dose
0013A Moderna COVID-19 Vaccine Administration Third Dose
91301 Moderna COVID-19 Vaccine
0031A Janssen COVID-19 Vaccine Administration Single Dose
0034A Janssen COVID-19 Vaccine Administration Booster
91303 Janssen COVID-19 Vaccine
0021A* Astra Zeneca COVID-19 Vaccine Administration First Dose
0022A* Astra Zeneca COVID-19 Vaccine Administration Second Dose
91302* Astra Zeneca COVID-19 Vaccine
0041A* Novavax COVID-19 Vaccine Administration First Dose
0042A* Novavax COVID-19 Vaccine Administration Second Dose
91304* Novavax COVID-19 Vaccine
0051A Pfizer-BioNTech COVID-19 Vaccine -Tris-Sucrose Administration First Dose
0052A Pfizer-BioNTech COVID-19 Vaccine -Tris-Sucrose Administration Second Dose
0053A Pfizer-BioNTech COVID-19 Vaccine -Tris-Sucrose Administration Third Dose
0054A Pfizer-BioNTech COVID-19 Vaccine -Tris-Sucrose Administration Booster
91305 Pfizer-BioNTech COVID-19 Vaccine
0064A Moderna COVID-19 Vaccine Low Dose Booster
91306 Moderna COVID-19 Vaccine Low Dose
0071A Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose Administration First Dose
0072A Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose Administration Second Dose
0073A Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose Administration Third Dose
91307 Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose
0081A* Pfizer-BioNTech COVID-19 Pediatric Vaccine – Tris-Sucrose Administration First Dose
0082A* Pfizer-BioNTech COVID-19 Pediatric Vaccine – Tris-Sucrose Administration First Dose
91308* Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose
M0201 Covid-19 Vaccine Home Administration
*Only to be included if granted full or emergency use approval by the Food and Drug Administration (FDA).

The following National Drug Codes (NDC) will be used for all vaccines provided in a Pharmacy by a pharmacist (Provider Type 03):
59267100001 Pfizer-BioNTech COVID-19 Vaccine Vial
59267100002 Pfizer-BioNTech COVID-19 Vaccine Carton
59267100003 Pfizer-BioNTech COVID-19 Vaccine Diluent
59267102501 Pfizer-BioNTech COVID-19 Vaccine Vial – Tris-Sucrose
59267105501 Pfizer-BioNTech COVID-19 Vaccine -Tris-Sucrose
59267007801* Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose
59267007804* Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose
80777027310 Moderna COVID-19 Vaccine Vial
80777027399 Moderna COVID-19 Vaccine Carton
59676058005 Janssen COVID-19 Vaccine
B. AHCCCS RESPONSIBILITIES

1. AHCCCS/Division of Health Care Management (DHCM) shall pull fully adjudicated and approved encounters with only the CPT codes listed above. These pulls shall be made in March 2022, September 2022, and a final pull and settlement in September 2023. The cost settlement shall be conducted and payments, including Premium Tax, shall be made after each data pull. The cost settlement shall be conducted multiple times to identify and settle any vaccine costs and Vaccine Administration Costs not previously settled. All COVID-19 encounters adjudicated and approved after the September 2023 data pull, shall not be cost settled and shall not be included in any reconciliations or other cost settlements.

2. AHCCCS shall provide the Contractor the data used for the cost settlement and provide written notice of the deadlines for review and comment by the Contractor. Upon completion of the review period, AHCCCS shall evaluate Contractor comments and make any adjustments to the data as warranted. AHCCCS shall then process a payment based on the total amount paid for COVID-19 vaccinations less the previous payments made including premium tax. Refer to Attachment A for an example cost settlement.

3. AHCCCS shall reimburse the Contractor the lessor of, the amount paid by the Contractor to the provider, or the Fee-For-Services (FFS) rates for the vaccine cost and Vaccine Administration Costs. All cost settlements to the Contractor shall include premium tax.

C. CONTRACTOR RESPONSIBILITIES

1. The Contractor shall submit encounters for COVID-19 vaccine costs and Vaccine Administration Costs and those encounters shall reach fully adjudicated and approved status by the date required by AHCCCS. AHCCCS shall only utilize fully adjudicated and approved encounters reported by the Contractor to determine the cost settlement.

2. The Contractor shall maintain financial statements that separately identify COVID-19 cost settlements as required by Contract and in the format specified in the AHCCCS Financial Reporting Guide.